Sonoyama T, Iwata S, Shinkai M, Iwata-Yoshikawa N, Shiwa-Sudo N, Hemmi T, Ainai A, Nagata N, Matsunaga N, Tada Y, Homma T, Omoto S, Yokokawa Shibata R, Igarashi K, Suzuki T, Hasegawa H, Ariyasu M. Results from a preclinical study in rodents and a Phase 1/2, randomized, double-blind, placebo-controlled, parallel-group study of COVID-19 vaccine S-268019-a in Japanese adults. Vaccine. 2023;41(11):1834-1847. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9755034/pdf/main.pdf
Meng F, Li W, Zhi F, Li Z, Xue Z, He S, Chen W, Chen Y, Xing X, Yao C, Wu Y, Zhang S. Antiperistaltic effect and safety of l-menthol oral solution on gastric mucosa for upper gastrointestinal endoscopy in Chinese patients: Phase III, multicenter, randomized, double-blind, placebo-controlled study. Digestive Endoscopy. 2021;33(7):1110-1119. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596731/pdf/DEN-33-1110.pdf
Takeuchi Y, Saito H, Makishima M, Yokoyama H, Yamaguchi T, Fujii H, Inoue E, Isemura T, Kondo S. Long-term safety of eldecalcitol in Japanese patients with osteoporosis: a retrospective, large-scale database study. Journal of Bone and Mineral Metabolism. 2022;40(2):275-291. https://pubmed.ncbi.nlm.nih.gov/35041084/
Iwata S, Sonoyama T, Kamitani A, Shibata R, Homma T, Omoto S, Igarashi K, Ariyasu M. Phase 1/2 clinical trial of COVID-19 vaccine in Japanese participants: A report of interim findings. Vaccine. 2022;40(27):3721-3726. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9122779/pdf/main.pdf
Shinkai M, Sonoyama T, Kamitani A, Shibata RY, Seki NM, Omoto S, Shinoda M, Sato T, Ishii N, Igarashi K, Ariyasu M. Immunogenicity and safety of booster dose of S-268019-b or BNT162b2 in Japanese participants: An interim report of phase 2/3, randomized, observer-blinded, noninferiority study. Vaccine. 2022;40(32):4328-4333. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212435/pdf/main.pdf
Miyazawa S, Takazono T, Hosogaya N, Yamamoto K, Watanabe H, Fujiwara M, Fujita S, Mukae H. Comparison of intra-familial transmission of influenza virus from index patients treated with baloxavir marboxil or oseltamivir using an influenza transmission model and a health insurance claims database. Clinical Infectious Diseases. 2022;75(6):927-935. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9522426/pdf/ciac068.pdf
Shimizu R, Sonoyama T, Fukuhara T, Kuwata A, Matsuo Y, Kubota R. Safety, Tolerability, and Pharmacokinetics of the Novel Antiviral Agent Ensitrelvir Fumaric Acid, a SARS-CoV-2 3CL Protease Inhibitor, in Healthy Adults. Antimicrobial Agents and Chemotherapy. 2022;66(10):e0063222. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9578392/pdf/aac.00632-22.pdf
Kato K, Doki Y, Ogata T, Motoyama S, Kawakami H, Ueno M, Kojima T, Shirakawa Y, Okada M, Ishihara R, Kubota Y, Amaya-Chanaga C, Chen T, Matsumura Y, Kitagawa Y. First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648/ONO-4538-50). Esophagus. 2023;20(2):291-301. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024660/pdf/10388_2022_Article_970.pdf
Uchino Y, Uchino M, Mizuno M, Shigeno Y, Furihata K, Shimazaki J. Morphological alterations in corneal nerves of patients with dry eye and associated biomarkers. Experimental Eye Research. 2023;230:109438. https://pubmed.ncbi.nlm.nih.gov/36933693/
Shimizu R, Sonoyama T, Fukuhara T, Kuwata A, Matsuzaki T, Matsuo Y, Kubota R. Evaluation of the Drug-Drug Interaction Potential of Ensitrelvir Fumaric Acid with Cytochrome P450 3A Substrates in Healthy Japanese Adults. Clinical Drug Investigation. 2023;43(5):335-346. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10177727/pdf/40261_2023_Article_1265.pdf
Sato S, Tomitori H, Okawa A, Akano K. Prescription patterns of analgesics in cancer patients with bone metastases in Japan: a retrospective database study. International Journal of Clinical Oncology. 2023; Epub ahead of print. https://pubmed.ncbi.nlm.nih.gov/37314600/